Abstract
Background
MAPK pathway inhibitors (MAPKi) have shown significant efficacy in treating childhood BRAF-activated brain tumors. For tumors harboring BRAFV600E mutations, the drugs are rarely curative, and patients can become refractory to treatment. MAPKi, combining X-radiation therapy (XRT), may improve the cure rate, but the development of XRT-resistance is a challenge.